Tourmaline Bio, Inc.
DelistedCIK 1827506fmd_0G1E3YDP81TRVC117HHTNA9Q4PManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2020 to Jun 30, 2025, 22 periods
Latest annual · FY2024
Millions- Operating income
- (90)
- Net income
- (73)
- Free cash flow
- (77)
Latest quarter · Q2 FY2025
Millions- Operating income
- (26)
- Net income
- (23)
- Free cash flow
- (20)
Tourmaline Bio, Inc. financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2024 | FY2023 | Change | Source |
|---|---|---|---|---|
| Operating income | -$89.7 million | -$45.4 million | 10-K 2025-03-13 · proof | |
| Net income | -$73.2 million | -$42.1 million | 10-K 2025-03-13 · proof | |
| Cash from operating activities | -$77.3 million | -$28.1 million | 10-K 2025-03-13 · proof | |
| Free cash flow | -$77.3 million | -$28.1 million | 10-K 2025-03-13 · proof | |
| Total assets | $309 million | $210.3 million | +46.9% | 10-K 2025-03-13 · proof |
| Total liabilities | $8.9 million | $5.3 million | +70.4% | 10-K 2025-03-13 · proof |
| Cash and cash equivalents | $30.5 million | $140.7 million | -78.3% | 10-K 2025-03-13 · proof |
- What was Tourmaline Bio, Inc.'s operating income in fiscal 2024?
- Tourmaline Bio, Inc. reported operating income of -$89.7 million for fiscal 2024 (the year ended Dec 31, 2024), against -$45.4 million the year before. Source: the 10-K filed with the SEC on Mar 13, 2025. SEC
- What was Tourmaline Bio, Inc.'s net income in fiscal 2024?
- Tourmaline Bio, Inc. reported net income of -$73.2 million for fiscal 2024 (the year ended Dec 31, 2024), against -$42.1 million the year before. Source: the 10-K filed with the SEC on Mar 13, 2025. SEC
- What was Tourmaline Bio, Inc.'s cash from operating activities in fiscal 2024?
- Tourmaline Bio, Inc. reported cash from operating activities of -$77.3 million for fiscal 2024 (the year ended Dec 31, 2024), against -$28.1 million the year before. Source: the 10-K filed with the SEC on Mar 13, 2025. SEC
- What was Tourmaline Bio, Inc.'s free cash flow in fiscal 2024?
- Tourmaline Bio, Inc. reported free cash flow of -$77.3 million for fiscal 2024 (the year ended Dec 31, 2024), against -$28.1 million the year before. Source: the 10-K filed with the SEC on Mar 13, 2025. SEC
- What are Tourmaline Bio, Inc.'s total assets?
- As of Dec 31, 2024, Tourmaline Bio, Inc. reported total assets of $309 million, against $210.3 million a year earlier (+46.9%). Source: the 10-K filed with the SEC on Mar 13, 2025. SEC
- What are Tourmaline Bio, Inc.'s total liabilities?
- As of Dec 31, 2024, Tourmaline Bio, Inc. reported total liabilities of $8.9 million, against $5.3 million a year earlier (+70.4%). Source: the 10-K filed with the SEC on Mar 13, 2025. SEC
- What are Tourmaline Bio, Inc.'s cash and cash equivalents?
- As of Dec 31, 2024, Tourmaline Bio, Inc. reported cash and cash equivalents of $30.5 million, against $140.7 million a year earlier (-78.3%). Source: the 10-K filed with the SEC on Mar 13, 2025. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1827506&period_type=annual&limit=5"Information only, not investment advice.